Effectiveness of Periodontitis Treatment on the Metabolic Activity of Symptomatic Carotid Atherosclerotic Plaque Responsible for Ischemic Stroke
Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jun 28, 2024
Trial Information
Current as of July 01, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating whether treating severe gum disease, known as periodontitis, can help reduce the activity of fatty deposits (atherosclerotic plaques) in the carotid arteries of patients who have experienced a type of stroke called ischemic stroke. Researchers believe that bacteria from gum disease may contribute to the formation of these dangerous plaques, which can lead to more strokes. By improving gum health, the trial aims to see if it can help lower the risk of future strokes in people who have already suffered one.
To participate in this study, individuals must be at least 18 years old and have had a minor ischemic stroke caused by a blood clot in the brain within the last 30 days. They must also have severe periodontitis and a specific level of plaque in their carotid arteries. Participants will be required to provide consent and be part of a social security system. Throughout the trial, they can expect to receive treatment for their gum disease and undergo assessments to monitor changes in their arterial health. This research is important as it may lead to new strategies for preventing strokes by focusing on oral health.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age ≥ 18 years
- • Minor ischemic stroke of the anterior circulation (NIHSS ≤ 5) of atherothrombotic origin according to the TOAST scale \<30 days
- • Atheroma plaque of the ipsilateral carotid bulb \>30% not eligible for intervention (endarterectomy or angioplasty-stenting)
- • Severe periodontitis (stage 3 or 4)
- • Signed informed consent
- • Affiliation to a social security scheme
- Exclusion Criteria:
- • \< 6 teeth
- • Without independent oral hygiene
- • Contraindications to PET scan
- • Known allergy to fluoro-deoxyglucose and its excipient
- • Immunosuppressive treatment
- • Uncontrolled diabetes
- • High risk of infective endocarditis
- • Organ transplant pending
- • Progressive infectious diseases
- • Active smoking not stopped
- • Patient deprived of liberty by judicial or administrative decision
- • Patient under legal protection (guardianship, curatorship)
- • Participation in another interventional research involving humans or being in the exclusion period following previous research involving humans
- • Pregnant or breastfeeding woman Patient under AME (state medical aid)
About Assistance Publique Hôpitaux De Paris
Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported